Reproductive Medicine Associates of New York Unveils Encouraging Data on Aneuploidy Rates in Embryos of Patients Carrying BRCA Mutation at 2016 ASRM Conference

Manhattan-based fertility center is the first to assess the rate of embryonic aneuploidy in patients who are BRCA 1 and 2 carriers

SALT LAKE CITY, Oct. 19, 2016 /PRNewswire-iReach/ -- Leading Manhattan-based fertility center Reproductive Medicine Associates of New York (RMA of New York), will present stimulating findings from a retrospective cohort study analyzing ovarian reserve and embryonic aneuploidy rates in BRCA 1 and 2 carriers as part of a set of 33 scientific abstracts at the 72nd annual meeting of the American Society of Reproductive Medicine (ASRM). The data concludes that although patients who carry the BRCA mutation are known to have an altered DNA repair mechanism, their embryos did not demonstrate increased rate of aneuploidy.

Fertility experts from RMA of New York sought to explore the link between BRCA mutations and decreased ovarian reserve more deeply than previous research has reported, by examining BRCA 1 (n=25) and 2 (n=17) patients of similar age and BMI who underwent controlled ovarian hyperstimulation from June 2009 to April 2016.  Both cohorts included cycles employing preimplantation genetic screening (PGS) via trophectoderm biopsy of blastocysts for both BRCA and chromosome copy number, and a total of 42 IVF cycles for fertility treatment (n=35) and oocyte cryopreservation (n=7) were analyzed, while ovarian reserve represented by mean day 3 FSH levels was analogous between patient cohorts. 

A rise in day 3 FSH was witnessed in BRCA 1 carriers vs. BRCA 2 carriers (0.39 vs. 0.14) for each incremental year in patient age, and there was a greater drop in the number of oocytes retrieved in BRCA 1 carriers (-2.5 vs -1.0) for every unit increase in day 3 FSH.  Study groups underwent equivalent treatment with cumulative gonadotropin dosages and experienced similar oocyte yield, fertilization and blastulation rates. PGS was performed in 16 cycles for BRCA 1 (n=9) and BRCA 2 (n=7) patients, revealing comparable rates of aneuploidy (43.9% vs. 42.9%, P<0.05).

Dr. Alan B. Copperman, Co-Director of RMA of New York and Vice Chairman of Obstetrics and Gynecology and Director of the Division of Reproductive Endocrinology and Infertility at the Icahn School of Medicine at Mount Sinai Hospital in New York, explains:

"As prior studies demonstrated reduced ovarian reserve and higher rates of infertility in BRCA 1 mutation carriers, it was believed that the mutated BRCA gene could lack the ability to repair double-strand breaks in DNA thereby accelerating oocyte aging, apoptosis and meiotic errors. Our team was determined to gain further insight on the link between these genetic mutations and the impact on our patients' reproductive potential, and the results of the study are extraordinarily reassuring to patients who carry BRCA mutations."

The RMA of New York study identified a trend toward accelerated age-related decline in ovarian reserve and oocyte yield in BRCA 1 carriers. Despite this decline, all patients had an adequate number of oocytes retrieved and blastocysts available for biopsy. The conclusive data determined that although patients who carry the BRCA mutation are known to have an altered DNA repair mechanism, their embryos did not demonstrate increased aneuploidy. RMA of New York is recommending that given the low incidence of the mutation, multi-center studies on BRCA mutation carriers who utilize PGS are needed to corroborate these preliminary findings.

Press interviews with RMA of New York can be arranged through Victoria Andretta, Director of Marketing (212-756-5777), vandretta@rmany.com.

About Reproductive Medicine Associates of New York, LLP

Reproductive Medicine Associates of New York (RMA of New York) is a national and international leader in state-of-the-art, compassionate reproductive medicine. The integrated team of physicians and scientists at RMA of New York has extensive experience and training in reproductive endocrinology, fertility, and urology, and consistently reports high success rates to the Society for Assisted Reproductive Technology (SART) and the Centers for Disease Control and Prevention (CDC). RMA of New York's achievements in the treatment of infertility have been internationally recognized, and the group maximizes access to care by assisting patients in exploring all available insurance coverage and financing options. RMA of New York has been recognized for its sensitivity to the LGBT community, women choosing single or same-sex motherhood, and women pursuing fertility preservation for elective and medical indications, including those in need of oncofertility services.

Headquartered in Midtown Manhattan, RMA of New York has three patient care facilities in Manhattan, as well as offices in Brooklyn, Garden City, and White Plains, NY. Additionally, RMA of New York has patient care facilities in Mexico City, Mexico. For more information, visit www.rmany.com.

Media Contact: Victoria Andretta, Reproductive Medicine Associates of New York, 212-756-5777, vandretta@rmany.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Reproductive Medicine Associates of New York



2016

Categories

Health & Living


Tags

Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries



Need Help